268 related articles for article (PubMed ID: 30711541)
21. Huntington's Disease: Relationship Between Phenotype and Genotype.
Sun YM; Zhang YB; Wu ZY
Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
[TBL] [Abstract][Full Text] [Related]
22. An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons.
Krach F; Stemick J; Boerstler T; Weiss A; Lingos I; Reischl S; Meixner H; Ploetz S; Farrell M; Hehr U; Kohl Z; Winner B; Winkler J
Nat Commun; 2022 Nov; 13(1):6797. PubMed ID: 36357392
[TBL] [Abstract][Full Text] [Related]
23. Huntingtin and Its Role in Mechanisms of RNA-Mediated Toxicity.
Heinz A; Nabariya DK; Krauss S
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357961
[TBL] [Abstract][Full Text] [Related]
24. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
[TBL] [Abstract][Full Text] [Related]
25. Cancer: From Wild-Type to Mutant Huntingtin.
Thion MS; Humbert S
J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
[TBL] [Abstract][Full Text] [Related]
26. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
27. CAG repeat expansion in the Huntington's disease gene shapes linear and circular RNAs biogenesis.
Ayyildiz D; Bergonzoni G; Monziani A; Tripathi T; Döring J; Kerschbamer E; Di Leva F; Pennati E; Donini L; Kovalenko M; Zasso J; Conti L; Wheeler VC; Dieterich C; Piazza S; Dassi E; Biagioli M
PLoS Genet; 2023 Oct; 19(10):e1010988. PubMed ID: 37831730
[TBL] [Abstract][Full Text] [Related]
28. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
29. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
30. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
[TBL] [Abstract][Full Text] [Related]
31. The MID1 Protein: A Promising Therapeutic Target in Huntington's Disease.
Heinz A; Schilling J; van Roon-Mom W; Krauß S
Front Genet; 2021; 12():761714. PubMed ID: 34659371
[TBL] [Abstract][Full Text] [Related]
32. Aberrant splicing of mutant huntingtin in Huntington's disease knock-in pigs.
Tong H; Yang T; Liu L; Li C; Sun Y; Jia Q; Qin Y; Chen L; Zhao X; Zhou G; Yan S; Li XJ; Li S
Neurobiol Dis; 2023 Oct; 187():106291. PubMed ID: 37716514
[TBL] [Abstract][Full Text] [Related]
33. Chromosomal instability during neurogenesis in Huntington's disease.
Ruzo A; Croft GF; Metzger JJ; Galgoczi S; Gerber LJ; Pellegrini C; Wang H; Fenner M; Tse S; Marks A; Nchako C; Brivanlou AH
Development; 2018 Jan; 145(2):. PubMed ID: 29378824
[TBL] [Abstract][Full Text] [Related]
34. Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntington's Disease Knock-In Mouse Models.
Franich NR; Basso M; André EA; Ochaba J; Kumar A; Thein S; Fote G; Kachemov M; Lau AL; Yeung SY; Osmand A; Zeitlin SO; Ratan RR; Thompson LM; Steffan JS
J Huntingtons Dis; 2018; 7(2):137-150. PubMed ID: 29843246
[TBL] [Abstract][Full Text] [Related]
35. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease.
Casaca-Carreira J; Toonen LJA; Evers MM; Jahanshahi A; van-Roon-Mom WMC; Temel Y
Biomed Pharmacother; 2016 Dec; 84():93-96. PubMed ID: 27639545
[TBL] [Abstract][Full Text] [Related]
36. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics.
Fienko S; Landles C; Sathasivam K; McAteer SJ; Milton RE; Osborne GF; Smith EJ; Jones ST; Bondulich MK; Danby ECE; Phillips J; Taxy BA; Kordasiewicz HB; Bates GP
Brain; 2022 Dec; 145(12):4409-4424. PubMed ID: 35793238
[TBL] [Abstract][Full Text] [Related]
37. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
[TBL] [Abstract][Full Text] [Related]
38. Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.
Miniarikova J; Evers MM; Konstantinova P
Mol Ther; 2018 Apr; 26(4):947-962. PubMed ID: 29503201
[TBL] [Abstract][Full Text] [Related]
39. Regulatory mechanisms of incomplete huntingtin mRNA splicing.
Neueder A; Dumas AA; Benjamin AC; Bates GP
Nat Commun; 2018 Sep; 9(1):3955. PubMed ID: 30262848
[TBL] [Abstract][Full Text] [Related]
40. Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington's disease models.
Mason MA; Gomez-Paredes C; Sathasivam K; Neueder A; Papadopoulou AS; Bates GP
Sci Rep; 2020 Aug; 10(1):14057. PubMed ID: 32820193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
